HDA UK Media And Political Bulletin – 23 January 2017
Pharmaphorum, 23 January 2017
The National Institute for Health and Care Excellence (NICE) and NHS England have outlined measures to cut the costs of expensive new medicines. Part of the plan involves fast-tracking medicines with a low budgetary impact to patients. Alongside this, proposals for a budget impact assessment – an ‘affordability check’ – constitute a less welcome part of the plan. This would mean that any drug looking to cost the NHS £20m or more per year would raise affordability discussions between a pharma company, NICE and NHS England. Above all, NHS wants to keeps its budget impact down. Proving to be a point of controversy with pharma companies and patient organisations, this NHS objective – manifested in the new affordability check – has already stirred considerable calls for renegotiation.
The Irish Examiner, Stephen Rogers, 23 January 2017
Today, Irish Health Minister Simon Harris will visit London with the hope of convincing the European Medicines Agency to relocate to Dublin. In the wake of the Brexit vote, various countries have been courting the Agency. “I am mindful of the consequences of Brexit for the agency and I believe that it will be essential to minimise the impact of a relocation, in particular by finding a solution that maximises retention of existing staff,” said Mr Harris. Mr Harris has said he will follow up today’s visit with a series of meetings in early February with officials and stakeholders in Brussels. Staff retention and Dublin’s English-speaking status are being presented as highly beneficial in providing a smooth transition for the Agency’s departure from Britain.
Parliament UK, Nicola Blackwood (Parliamentary Under-Secretary of State for Health), 20 January 2017
The Department of Health and the Association of the British Pharmaceutical Industry are to amend the 2014 Pharmaceutical Price Regulation Scheme (PPRS) to ensure that the scheme continues to deliver its objectives of predictability and stability to Government and industry. Additionally, it looks to safeguard costs, so that branded medicines to the NHS stay within affordable limits. Implicit in this is the Government’s recognition of the pharmaceutical industry’s contributions, and the financial challenges facing the NHS. The Department of Health has published a document setting out further details entitled “Pharmaceutical Price Regulation Scheme (PPRS) 2014: revised payment percentages at December 2016”. It can be read in full here.
Pharmaphorum, 23 January 2017
Plans to cut the cost of expensive new medicines could mean delays getting them to patients in England, according to the UK pharma industry.
NICE and NHS England have been consulting on changes to processes that will fast-track medicines with low budgetary impact to patients.
But also included is a proposal for a budget impact assessment – a kind of ‘affordability’ check. This would mean any drug set to cost the NHS £20 million or more a year would trigger affordability discussions between a pharma company, NICE and NHS England.
Above that threshold, NHS organisations will begin talks with drug companies to try to get the price down.
NHS England has pushed for the new budget impact assessment to prevent problems similar to those caused by hepatitis C drugs such as Gilead’s Sovaldi (sofosbuvir). NICE ruled Sovaldi to be cost effective – but this didn’t reflect the overall, upfront cost – the affordability of the drug.
NHS England has resorted to rationing to keep its budget impact down, something which has proven controversial with pharma companies and patient organisations.
In 2015/16 NHS spending on Gilead’s Harvoni (sofosbuvir+ledipasvir) and Sovaldi for hepatitis C was £154 million, although AbbVie’s Humira (adalimumab) inflammatory diseases drug had the largest budget impact, costing the NHS almost £417 million.
The industry says that the new affordability check is unfair – as NICE already screens new medicines for cost effectiveness, and the PPRS pricing system limits overall NHS drug spending.
ABPI chief executive, Mike Thompson, said: “The ABPI agrees with the NHS England’s objective of developing a workable solution for managing the introduction of new medicines which are likely to create significantly high costs to the NHS.”
“However, given that all new drugs approved by NICE have already gone through a process to ensure they are cost-effective and clinically beneficial, the proposal to impose a £20million budget cap on these medicines is both heavy-handed and unrealistic and will mean more patients face delays in accessing appropriate NHS care.
“Better long term planning by the health service would ensure that major breakthroughs are managed into the NHS in an appropriate and affordable way and with less disruption.”
The ABPI said it supports plans to fast-track medicines with an estimated budget impact of less than £10,000 per Quality Adjusted Life Year.
But it and UK biotech industry association the BIA both warned that NICE’s proposals could delay or prevent access to drugs for ultra-rare diseases.
The consultation also proposes a £100,000 cost per QALY threshold for rare and ultra-rare disease drugs would receive automatic funding.
Above this threshold, ultra-rare disease drugs would receive cost-effectiveness assessments and the BIA and ABPI are concerned this could lead to many such drugs being rejected or delayed.
“We believe that this will have a detrimental impact on the development of new products for those who desperately need them and that this this proposal should be paused while a better solution is identified,” said Thompson.
These new checks on affordability send out a message is in clear contradiction to the government’s proposed life sciences industrial strategy. Theresa May’s government is promising to help make the UK a world leading life sciences market, but pharma and biotech says this can’t be fully achieved if the NHS doesn’t use its new medicines.
This argument is one that will be clearly played out behind the scenes, but as the government is currently refusing to give the NHS extra money to cope with growing demand, it is also unlikely to give way on the new proposals for NICE.
There is some hope that the ABPI and the government could negotiate a new ‘value-based’ pricing system, but this is unlikely to emerge until 2019, after the existing PPRS pricing system expires.
The Irish Examiner, Stephen Rogers, 23 January 2017
Health Minister Simon Harris will today travel to London to try to convince the European Medicines Agency of the merits of relocating to Dublin.
The EU agency will have to leave Britain as a result of Brexit and the Government has made no secret of its desire to attract it to Ireland.
Today, Mr Harris will meet with the agency’s executive director, Professor Guido Rasi, and members of his team.
“I am mindful of the consequences of Brexit for the agency and I believe that it will be essential to minimise the impact of a relocation, in particular by finding a solution that maximises retention of existing staff,” said Mr Harris.
“The Government has endorsed my request that Ireland would seek to have the EMA relocate to Dublin.”
Dublin is being presented as a viable location on the back of its ability to maximise retention of existing staff; the fact that it is an English-speaking location and English is the agency’s working language; and the fact that the Health Products Regulatory Authority here would be able to provide strong support.
Mr Harris has said he will follow up today’s visit with a series of meetings in early February with officials and stakeholders in Brussels.
From Factory to Pharmacy
As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.See the Infographic
Apply to become a Member
Membership of the HDA guarantees your organisation:
- Access to leading policy and industry forums of debate and discussion
- Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
- Representation on HDA working parties, including the Members’ Liaison Group
- A daily Political and Media Bulletin and HDA Newsletters
- Access to HDA policy documents and all sections of the HDA website
- Branding and marketing opportunities